230 related articles for article (PubMed ID: 19806789)
21. Heterogeneity of multiorgan metastases of human lung cancer cells genetically engineered to produce cytokines and reversal using chimeric monoclonal antibodies in natural killer cell-depleted severe combined immunodeficient mice.
Sone S; Yano S; Hanibuchi M; Nokihara H; Nishimura N; Miki T; Nishioka Y; Shinohara T
Cancer Chemother Pharmacol; 1999; 43 Suppl():S26-31. PubMed ID: 10357555
[TBL] [Abstract][Full Text] [Related]
22. Identification of genes potentially involved in bone metastasis by genome-wide gene expression profile analysis of non-small cell lung cancer in mice.
Dat le T; Matsuo T; Yoshimaru T; Kakiuchi S; Goto H; Hanibuchi M; Kuramoto T; Nishioka Y; Sone S; Katagiri T
Int J Oncol; 2012 May; 40(5):1455-69. PubMed ID: 22294041
[TBL] [Abstract][Full Text] [Related]
23. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
24. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Kawano T; Sone S
Int J Cancer; 1998 Nov; 78(4):480-5. PubMed ID: 9797137
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms of breast cancer metastases to bone.
Guise TA; Kozlow WM; Heras-Herzig A; Padalecki SS; Yin JJ; Chirgwin JM
Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S46-53. PubMed ID: 15807924
[TBL] [Abstract][Full Text] [Related]
27. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
28. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Rosen L; Harland SJ; Oosterlinck W
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S19-24. PubMed ID: 12562047
[TBL] [Abstract][Full Text] [Related]
29. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
[TBL] [Abstract][Full Text] [Related]
30. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells.
Yano S; Nishioka Y; Izumi K; Tsuruo T; Tanaka T; Miyasaka M; Sone S
Int J Cancer; 1996 Jul; 67(2):211-7. PubMed ID: 8760590
[TBL] [Abstract][Full Text] [Related]
31. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
[TBL] [Abstract][Full Text] [Related]
32. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Body JJ
Breast; 2003 Aug; 12 Suppl 2():S37-44. PubMed ID: 14659142
[TBL] [Abstract][Full Text] [Related]
33. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
34. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone.
Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR
J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581
[TBL] [Abstract][Full Text] [Related]
35. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A.
Hashimoto K; Ochi H; Sunamura S; Kosaka N; Mabuchi Y; Fukuda T; Yao K; Kanda H; Ae K; Okawa A; Akazawa C; Ochiya T; Futakuchi M; Takeda S; Sato S
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2204-2209. PubMed ID: 29440427
[TBL] [Abstract][Full Text] [Related]
36. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
37. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice.
Iwasaki T; Yamashita K; Tsujimura T; Kashiwamura S; Tsutsui H; Kaisho T; Sugihara A; Yamada N; Mukai M; Yoneda T; Okamura H; Akedo H; Terada N
J Immunother; 2002; 25 Suppl 1():S52-60. PubMed ID: 12048351
[TBL] [Abstract][Full Text] [Related]
39. Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Ricciardi S; de Marinis F
Rev Recent Clin Trials; 2009 Sep; 4(3):205-11. PubMed ID: 20028333
[TBL] [Abstract][Full Text] [Related]
40. PET Tracer
Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]